Anti-PD-L1 antibody and uses thereof
US11512131B2 · kind B2 · utility
0Cited by
14References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 27, 2018 |
| Grant date | Nov 29, 2022 |
| Priority date | — |
| Expiry date | Dec 27, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a novel antibody and an antibody fragment that specifically bind to PD-L1 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and a related use. Furthermore, the invention relates to a therapeutic and diagnostic use of these antibodies and antibody fragments. Particularly, the invention relates to a combined treatment of these antibodies and antibody fragments with other therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.